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Abstract: Malaria is a parasitic tropical disease that kills around 600,000 patients every year.
The emergence of resistant Plasmodium falciparum parasites to artemisinin-based combination
therapies (ACTs) represents a significant public health threat, indicating the urgent need for new
effective compounds to reverse ACT resistance and cure the disease. For this, extensive curation and
homogenization of experimental anti-Plasmodium screening data from both in-house and ChEMBL
sources were conducted. As a result, a coherent strategy was established that allowed compiling
coherent training sets that associate compound structures to the respective antimalarial activity
measurements. Seventeen of these training sets led to the successful generation of classification
models discriminating whether a compound has a significant probability to be active under the
specific conditions of the antimalarial test associated with each set. These models were used in
consensus prediction of the most likely active from a series of curcuminoids available in-house.
Positive predictions together with a few predicted as inactive were then submitted to experimental
in vitro antimalarial testing. A large majority from predicted compounds showed antimalarial activity,
but not those predicted as inactive, thus experimentally validating the in silico screening approach.
The herein proposed consensus machine learning approach showed its potential to reduce the cost
and duration of antimalarial drug discovery.
Keywords: antimalarial; quantitative structure-activity relationships (QSAR); curcuminoid;
Michael addition; Plasmodium falciparum; thioredoxin reductase; in silico
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1. Introduction
Malaria is a major tropical parasitic disease that each year affects 500 million humans worldwide
and kills 600,000 patients, in particular children younger than five years-old and pregnant women in
Sub-Saharan Africa. Although previously limited to tropical countries, the disease is now progressing
in non-endemic regions as a result of both global warming and migration flows. Five parasitic species
of the genus Plasmodium, namely P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi, cause malaria,
but the most prevalent and dangerous P. falciparum is responsible for the severe form of the disease,
such as cerebral malaria.
Through the bite of a mosquito, sporozoites enter the bloodstream and infect the liver, where they
divide and mature. Thousands of merozoites are subsequently produced and invade erythrocytes to
initiate the intraerythrocytic cycle. The developmental cycle in the erythrocyte lasts, on average, 48 h
for P. falciparum upon which new merozoites are released to reinvade other erythrocytes. Some of the
merozoites develop into gametocytes that are taken by the mosquito during feeding, and the cycle
is repeated. Digestion of host hemoglobin during the erythrocytic cycle is an important process for
providing amino acids for parasitic development. The parasite detoxifies free heme as side product of
hemoglobin digestion by bio-mineralization into the malarial pigment called hemozoin [1,2]. This heme
detoxification is the target pathway of numerous antimalarial drugs, most of them belonging to the
aminoquinoline series [3].
Plasmodium parasites are exposed to high fluxes of reactive oxygen species due to both
the host immune response to infection and to hemoglobin digestion. To survive, they
need highly active intracellular antioxidant systems providing a steady flux of glutathione
(L-γ-glutamyl-L-cysteinylglycine, GSH) and reduced thioredoxin (Trx(SH)2). The most important
antioxidative systems are based on both the glutathione reductases (GR) of the parasitized host
erythrocyte and the thioredoxin reductase (TrxR) of the malarial parasite. Both flavoenzymes
respectively catalyze the reduction of the disulfide bridge of oxidized glutathione (GSSG) and oxidized
thioredoxin (Trx(S)2) into the thiol forms GSH and Trx(SH)2, according to Equations (1) and (2).
Similar to the situation in other eukaryotes, GSH is the major low molecular mass antioxidant in
malarial parasites. While classical glutathione peroxidases (Gpx) and catalase are absent, GSH
plays a major role by directly reacting with hydroperoxides and by modulating enzyme activity via
glutathionylation. Besides the GR and TrxR systems, Plasmodium has developed multiple antioxidant
defense mechanisms (for reviews, see [4,5]), based on iron (Fe)-superoxide dismutase (SOD) and
manganese (Mn)-SOD, as well as four unique selenoproteins, which may also represent components
of the redox-regulatory network (for a review, see [6]).
GSSG`NADPH`H` GRÑ 2GSH`NADP` (1)
TrxS2 `NADPH`H` TrxRÑ Trx pSHq2 `NADP` (2)
Both the glutaredoxin using the low-molecular weight thiol GSH and the thioredoxin pathway
represent the two independent arms of the reducing system that assists the disulfide bond reduction
and activation of many thioredoxin-dependent proteins [4], in particular GSSG reduction in malarial
parasites. Therefore, both the glutathione and thioredoxin systems, extensively characterized in
P. falciparum, interact closely to maintain a redox balance [7].
Hemoglobin digestion occurs in the food vacuole of P. falciparum and bursts into an intense
liberation of reactive oxygen species (ROS), pro-oxidative heme, iron and GSSG. Heme can be degraded
by GSH [8] and was shown to be inhibited by the antimalarial drugs, chloroquine and the phenolic
Mannich base amodiaquine [9]. These two 4-aminoquinolines are also potent inhibitors of heme
detoxification. The reaction of iron(II) with H2O2 is known to generate the highly toxic hydroxyl radical
(Fenton reaction). During these processes, regulation of GSH homeostasis in P. falciparum depends
on both GSH/GSSG efflux [10] and the de novo biosynthesis of the tripeptide [11]. Oxidation of
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GSH is balanced through an active GR redox cycle, while efflux is counteracted by an active GSH
biosynthesis. Another central component of the antioxidative defense system of P. falciparum is
the cytosolic thioredoxin-1 (Trx1), which directly detoxifies hydroperoxides and reduces GSSG and
S-nitrosoglutathione (GSNO) [12]. Furthermore, Trx1 interacts with a range of proteins involved in, for
example, protein folding, transcription and translation, signal transduction, glycolysis and hemoglobin
catabolism [13]. TrxR has been shown to be an essential protein for the survival of P. falciparum
blood stages [14], and therefore, a highly interesting target for specific inhibitors [15–21] to combat
malarial parasites.
Among the TrxR inhibitors, the natural product curcumin was reported to induce reactive oxygen
species (ROS) in some cancer cells [22,23], and this is consistent with the irreversible inhibition
of human TrxR in which curcumin alkylates residues (Cys496/Sec497) in the catalytic site of this
enzyme [19]. However, the antimalarial activity of curcumin was shown not to correlate with
P. falciparum TrxR inhibition [24], suggesting that the compound could kill malarial parasites by
another mechanism, e.g., by ROS induction. It is known that innate immune responses against the
parasite play a major role in the regulation of blood stage parasitemia through the phagocytosis
of P. falciparum parasitized red blood cells by monocytes/macrophages. With the approach aiming
at the identification of therapeutic targets to enhance this type of immunity, a key study showed
that CD36 expression and CD36-mediated P. falciparum phagocytosis by curcumin are dependent on
ROS production [25]. Because curcuminoids are known as ROS-inducing agents, these drugs can
be specifically targeted for killing malarial parasites that already express high ROS levels. Therefore,
enhancing innate immunity with immunomodulatory compounds like curcuminoids might contribute to
the clearance of malaria parasites, including drug-resistant parasites. The drug combination of ACTs with
curcuminoids will represent a valuable tool in optimizing the clearance of malaria parasites in vivo [26].
The purpose of the current study was to find new promising compounds with antimalarial
activity with the aid of in silico methods that allow one to significantly accelerate the discovery
of novel bioactive chemical entities. In particular, chemoinformatics relies on the existing available
experimental data, allows extracting knowledge on structure-activity relationships and applies this
knowledge in suggesting novel potentially bioactive compounds. In this article, we focused our efforts on
the computer-aided discovery of novel antimalarial curcuminoid derivatives, with the following key steps:
(a) Collection and curation of experimental data
(b) Knowledge extraction, by construction of structure-activity relationship models
(c) Virtual screening of candidate collections and selection of candidates with best predicted
properties using the above built models
(d) Experimental in vitro testing of selected candidates
In order to learn the structure-activity relationships, a maximum of reliable experimental
information is required, which makes Step (a) the pivotal part of the undertaking. The particular
problem in antimalarial research is not the scarcity, but the heterogeneity of the data.
Potentially relevant data may cover anything from in vitro inhibitory assays on involved biological
targets to functional assays using Plasmodium cultures. In this work, we only focused on the latter.
However, screening data on P. falciparum can be done in very different ways, because there are various
experimental conditions using different P. falciparum strains. An important challenge consisted of
managing and fusing the various data sources: the in-house data of Davioud-Charvet’s team and
literature data from the malaria subset of ChEMBL. Following this crucial step, predictive model
building (b) followed a state-of-the-art protocol (see the Methods for more details), leading to a series
of best models (according to statistical validation criteria) used to predict the antimalarial activity of
candidate compounds, at Step (c).
Candidate molecules were previously designed and synthetized by chemists for other
applications [27–31]. These were both symmetrical and dissymmetrical diarylideneacetone
(DAA) derivatives with variously-substituted aryl or heteroaryl rings, as well as symmetrical
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2,6-diaryltetrahydrothiopyran-4-ones (2,6-DATHTPs). Experimental testing (d) of the candidates
predicted to be active in silico at Step (c) led to the discovery of novel antimalarial compounds in
a very cost-effective manner.
2. Results
Seventy two in-house compounds (35 DAA (Table S1) and 37 2,6-DATHTP (Table S2)) were
virtually screened using support vector machine (SVM) classification consensus models. Out of those,
thirty one candidates (19 DAAs and 12 2,6-DATHTPs) with the best predicted properties using the
above built models were selected and tested in vitro for both antimalarial potencies (IC50: inhibitory
concentration 50%) against the 3D7 P. falciparum strain and cytotoxicity (CC50: cytotoxic concentration
50%) against the human fibroblast MRC-5 cell line (Table 1).
Table 1. Structures of diarylideneacetones (DAAs), antimalarial effects, cytotoxicity and predicted activities.
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The antimalarial activity of DAAs and 2,6-DATHTPs was assessed in cell-based in vitro cultures
of the 3D7 P. falciparum strain (Tables 1 and 2). Amongst in vitro tested DAAs, 16 compounds
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(A1–A10, A12–A13) were predicted as active, and 12 compounds (A1–A12) were observed as active.
Three compounds (A11, A18, A19) were predicted to be inactive, and seven compounds (A13–A19)
were found inactive against the 3D7 P. falciparum strain. Amongst in vitro tested 2,6-DATHTPs, eleven
compounds (B1–B11) were predicted to be active, and five compounds were found as active (B1–B5).
One compound was predicted to be inactive against the 3D7 P. falciparum strain and was indeed found
as inactive (B12).
Table 2. Structures of 2,6-diaryltetrahydrothiopyran-4-ones (2,6-DATHTP), antimalarial effects,
cytotoxicity and predicted activities.
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IC50 ˘ SD (nM) CC50 (µM) CC50/IC50 A/I
B1 30.3 ˘ 6.1 >64.00 >2112.2 A [28]
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B3 40.1 ˘ 7.3 8 199.5 A [29,31]
B4 60.4 ˘ 10.2 nd nd A [28]
B5 240.1 ˘ 48.1 8.06 33. A [29,31]
B6 >500 >64.00 <128 A [29,31]
B7 >500 >64.00 <128 A [29,31]
B8 >500 >64.00 <128 A [28]
B9 >500 7.89 <15.8 A [29,31]
10 >5 0 >64.00 <12 A [29,31]
B11 >500 7.47 <14.9 A [29,31]
B12 >500 4.96 <9.9 I [29,31]
chloroquine 20.3 ˘ 5.2 >64.00 >3158 A
a The standard drug chloroquine served as the positive control for the P. falciparum 3D7 strain. b The cytotoxicity
reference drug tamoxifen exhibited CC50-values of 9.12 µM (mean of 7 values) against human MRC-5 fibroblasts.
“A” me s “active”, “I”, “inactive”; “SI” stan s for “selectivity index” = CC50/IC50; “nd” means “not determined”.
Amongst the DAAs, three compounds showed CC50 > 64.00 µM and were classified as not
cytotoxic; six compounds (A3, A5, A9, A17 and A19) showed CC50 values from 29.37 µM–62.28 µM
and were classified as rather not cytotoxic; eight compounds (A1 A2, A7, A10, A13, A14, A16 and
A18) showed CC50 values from 1.06 µM–5.36 µM and were classified as rather cytotoxic (Table 1).
The most cytotoxic was A18 (CC50 = 1.06 µM), with the same substitution pattern found on both aryl
rings as found in curcumin. Amongst the 2,6-DATHTPs, five compounds (B1, B6–B8 and B10) showed
CC50 > 64.00 µM in the assays and were classified as not cytotoxic; five compounds (B3, B5, B9, B11
and B12) showed CC50 values from 4.96 µM–8.00 µM and were classified as moderately cytotoxic (Table 2).
Overall, the in silico model predicted 27 compounds to be active, out of which 17 were confirmed
experimentally, whereas 10 compounds did not live up to the expectations set by the prediction.
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Most of the correct predictions were obtained when at least one of the 17 used consensus models
“voted” the compounds to be active by a large majority of >70%. The alternative selection scheme of
compounds voted active by at least two models at a low majority >50% was less successful. A strong
majority in consensus voting is, as already reported [33], a strong trustworthiness score of in silico
predictions. All three compounds predicted as inactive were indeed found as inactive. In other words,
all of the actual active one within the tested subset (17) were correctly assigned an “A” label by the in
silico method, yielding a model sensitivity (or recall) of 100%. However, only three that were inactive
of the actual 13 were correctly recognized as inactive; hence, the specificity score of the in silico method
was only 0.23. With a balanced accuracy index of 0.62 (defined as the mean of the above-mentioned
sensitivity and specificity scores) in an actual, prospective prediction challenge, the in silico model has
proven effective.
3. Discussion
3.1. Known Antimalarial Curcuminoids and Unsaturated/Phenolic Mannich Bases
Curcumin is the major component of extracts of Curcuma longa, which is the base of turmeric
spice. Besides its gustative and food coloring usage (food additive E100), this spice is known since
antiquity for its therapeutic properties. Curcumin was reported to display a broad pattern of biological
activities through pleiotropic and epigenetic mechanisms [34]. The turmeric called curcuma contains
3%–5% curcuminoids (50%–60% curcumin) and up to 5% essential oils and resins. Curcuma longa
extracts not only contain curcumin, but also demethoxycurcumin and bisdemethoxycurcumin, as
well as monocarbonyl curcuminoids, such as the “short” curcuminoid DAA analogues (R = H, or
R = OMe; Figure 1) [35]. As for curcumin, DAA from Curcuma species are monocarbonyl curcumin
analogues that were reported to display numerous biological activities [36–39], from anti-inflammatory,
anticancer, antioxidant to antiparasitic activities, including antimalarial activities [24,26,40–43].
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Figure 1. Structures of natural curcumin and diarylideneacetone (DAA) derivatives that have been
identified in Curcuma extracts and the structure of the related unsaturated ketonic Mannich bases.
Curcumin and curcuminoids are bis(Michael acceptors) and are also related to unsaturated
Mannich bases (Figure 1), which possess two electrophilic centers: (i) the α,β-unsaturated ketone is
visible per se; and (ii) the other is masked and revealed only after a base-dependent deamination of the
α-amino ketone. Michael addition of two nucleophiles (e.g., thiols from proteins) leads to a bis(adduct)
product, upon an elimination of the dialkylamino group promoted by a base-catalyzed enolization of
the ketone. From a screening of 350,000 compounds of the Pfizer library, unsaturated Mannich bases
were identified to be efficient mechanism-based inhibitors of P. falciparum TrxR [17]. Induction of ROS
by curcuminoids and related unsaturated Mannich bases has been proposed to occur via redox-cycling
following Michael addition of thiols to the enone, sulfide oxidation, syn-elimination, irreversible
formation of thiol overoxidation and continuous NADPH consumption [31,44].
Numerous Michael acceptors, including phenolic and C-Mannich bases, possess antimalarial
potencies. First, the Mannich base pharmacophore was introduced in the 4-aminoquinolines in the
50’s of the last century, after the discovery of chloroquine, and was revealed with the discovery
of amodiaquine [45] and then with tebuquine [46], amopyroquine [47] and pyronaridine [48].
These approved drugs were particularly effective at combating chloroquine-resistant malarial parasites,
likely because, following phenol oxidation, these agents participated in glutathione depletion following
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Michael addition to the electrophilic sites of the molecule in the malarial parasites. These last effects
contribute to reverse chloroquine resistance by counteracting the enhanced glutathione P. falciparum
chloroquine resistance transporter-mediated transport in the digestive vacuole of CQ-resistant
parasites [10]. Compared to amodiaquine, more metabolically-stable Mannich side chains were
introduced in tebuquine (the addition of a 4-chlorophenyl group and replacement of the diethylamine
by a N-t-butylamine side chain), amopyroquine (replacement of the diethylamine by a N-pyrrolidine)
and pyronaridine (characterized by two Mannich bases’ side chains, replacement of the quinoline
heterocycle by an aza-acridine and replacement of the diethylamine by a N-pyrrolidine side chain).
Therefore, by delaying the Michael addition of nucleophiles to the electrophilic sites in the human host,
phenolic Mannich bases behave as prodrugs of Michael acceptors. Other strategies to temporarily
mask the reactive phenolic Mannich base were developed by designing Trojan horses drugs, either
by tethering the phenol or the ketonic Mannich base with moieties that are recognized by a parasitic
transporter to favor the drug uptake [49–51] or by designing hybrid molecules built from a Mannich
base and a 4-aminoquinoline via an amine group [52]. The latter group was expected to be dealkylated
under oxidative conditions found in malarial parasites to release two reactive entities, i.e., the Michael
acceptor and the 4-aminoquinoline vector.
More recently, the alkaloids febrifugine and isofebrifugine, first found in the Chinese plant
Dichroa febrifuga and later in the common hydrangea, have attracted considerable attention due to
their potent antimalarial activity [53], opening the path for the pipeline of new antimalarial leads.
The febrifugine structure of this plant-derived natural product, with its β-amino-ketone motif, is
a Mannich base susceptible to Michael addition of thiols following deamination. Until now, the potential
of febrifugine to react with nucleophiles under specific conditions found in malarial parasites has not
been reported. As mentioned earlier, numerous acyclic Mannich bases were previously identified
as P. falciparum TrxR inhibitors [17]. A recent review about Mannich bases identified as inhibitors
of various enzymes or ligands for receptors was dedicated to their structure-activity relationships
covering a broad panel of biological applications useful for medicinal chemistry and drug design [54].
3.2. Compound Class Selection and Organic Synthesis
Considering the numerous evidences that curcuminoids, and particularly DAAs, are potent
antimalarial products, we focused our interest on this series. Both the ChEMBL database [55] and the
in-house EDC database already contained this type of structure. As second category composed of
2,6-DATHP derivatives was also selected, as these may be seen as a prodrug of DAA and therefore of
great interest as antimalarial candidates. Both series were recently synthesized in-house as previously
described [27–31].
3.3. Virtual Screening of Candidate Collections Using the SVM Classification Consensus Models and the
Selection of Candidates with the Best Predicted Properties
Most of the compounds predicted as active (Tables 1 and 2) and also a few compounds (A11,
A18, A19, B12) that were predicted as inactive against P. falciparum were selected for in vitro testing
to validate the SVM classification consensus models. The decision on which compounds to test was
based on the consensual nature of the models.
The 17 models selected for their cross-validated balanced accuracy scores above 0.7 are based on
sets of various sizes—the largest spanning almost 1000 compounds, the smallest based on hardly more
than 50 molecules. Note, however, that even the latter successfully withstood the quite challenging
leave-1/3-out, multiply repeated cross-validation protocol. It is interesting to note that the largest set
for which modelling was attempted (ChEMBL1054503, [55]), including 13,533 entries, led to a rather
robust cross-validated balanced accuracy score of 0.69, making it a near miss for selection within the set
of herein used models. Set size is thus not the determining factor of their modelability, and the relative
success of dealing with compound sets of the above-mentioned sizes is a proof of the robustness of the
modelling protocol, which was already validated in external prediction challenges [56].
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Each of the 17 consensus models returns a real-value likelihood (percentage) of the candidate
to qualify as active with respect to the associated property. A likelihood around 50% is inconclusive,
since this means that, out of the individual distinct equations composing the consensus model, those
predicting “active” and those predicting the opposite are roughly equally numerous. The closer to
100%, the higher the trust in the hypothesis that a compound will be active. Furthermore, these different
“properties” are all antimalarial activity measures. It is unclear how the prediction of activity with
respect to the testing protocols underlying the 17 modeled categories relates with the actual propensity
of the compound under the current test conditions. The latter conditions do not completely match any
of those associated with the 17 modeled properties, even though the herein used parasitic strain (3D7)
and assay principle (SYBR green) are sometimes shared. For this reason, the simple rule used here
was to consider a compound to be worth testing (assigned an in silico status of “A” for active by the
virtual screening procedure, see Tables 1 and 2) if at least one of the 17 predictors signaled “active”
likelihood above 70%, or if more than one of the 17 predictors indicated activity likelihoods above 50%.
3.4. Experimental in Vitro Testing of the Selected Candidates and Structure-Activity Relationships
Finally, 41 compounds were assigned an “active” status out of the 72 submitted to virtual
screening (both structural series confounded; see Tables 1 and 2). This number was still beyond the
planned biological testing effort, and therefore, only 27 of them were eventually taken. Furthermore,
four additional compounds that were predicted as inactive in virtual screening were nevertheless
considered for testing, because they were known as active in other in vitro parasitic tests [30,31]. Hence,
this approach was an opportunity to verify their effect on plasmodial cultures, in spite of the virtual
screening result. This is also very valuable for the validation of the virtual screening, as it provides the
opportunity to verify whether those predicted as inactive are not “false negatives”.
A total of 31 compounds (12 DAA and 19 2,6-DATHTP: 27 of in silico status “A” vs. four “I”)
were tested for both their antimalarial potencies against P. falciparum and cytotoxicity against human
fibroblasts MRC-5 strain (Tables 1 and 2). Within the new series of curcuminoid derivatives, novel
structure-activity relationships can be evidenced, since the series covers significant chemical diversity:
electron-donating and -withdrawing groups, lipophilic atoms, aromatic and polar residues, variations of
the aryl/heteroaryl rings in both positions of the terminal 1,5-di(hetero)aryl penta-1,4-dien-3-one chain.
As can be seen from Table 1, electron-withdrawing substituents on both aryl rings led to
an increase of the antiplasmodial activity. The results showed a potent antimalarial activity for
DAA bearing the same electron withdrawing group (EWG) groups (halogen atoms like Cl, F) on
both aryl moieties or for heteroaryl substituted-DAA containing pyridine rings. For those most
potent compounds with pyridine rings, toxicity accompanied the antimalarial potency, suggesting
non-specific effects. On the contrary, the DAA bearing the same electron donating groups (EDG) groups
(Me, OMe, NH2, NMe2 groups) on both aryl moieties were shown to be less active at killing parasites,
with a proportional trend to display a lower cytotoxicity against human MRC-5 cells. Noteworthy,
the presence of an ortho-hydroxyl substituent on the aromatic rings of the DAA and the associated
increased antimalarial activity (IC50 30.2 nM for Compound A2 vs. >500 nM for Compound A18)
might be explained by the enhanced reactivity of the thiolate of the target (enzyme) thiols (resulting
from lowering the pKa) through inductive/hydrogen bonding of the phenolic group (Figure 2), as
previously observed [36].
Interestingly, the highest selectivity index (SI) was found for dissymmetrical DAAs with a “push-pull
effect” when an EWG group was present on one aromatic ring and an EDG on the second aromatic ring
of the DAA (e.g., SI values of 292.4 for Compound A5, or 625 for Compound A3, or 577.6 for Compound
A6). Among all DAAs in Table 1 measured for antimalarial activity, we found discrepancies on the
antimalarial potencies for four compounds in comparison with data reported previously [32]. However,
as these published measurements did not show the data of positive controls (chloroquine, artemisinin),
no conclusion can be drawn. Two other sets of published data [41,43] showed IC50 values in the sub- or
low µM range close to the values found for our present series studied in this work.
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and so numerous (2870) that their in-depth analysis in view of attempted fusion cannot be pursued
“by hand”, as done in this work (see the following paragraphs). The invested human effort of
analysis per series would not be justified by the low number of entries (<50) per series that might be
“recovered” by association to large training sets regrouping all the “compatible” data. Text mining
tools should be developed for such a task, and this was beyond the scope of the present work. Herein,
thirty series containing more than 50 compounds were scrutinized in terms of data quality, keeping
only dose-response-based AV and discarding series with too few active compounds, or redundant
series (same set of molecules, tested under nearly identical conditions with nearly identical results).
Only seven series fulfilled these criteria and were used in further work.
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After upl ading/manual collection of in-house/ChEMBL comp und series, the structural
curation work, the rejection of chemically-unusable (too large, too small, too “exotic”) structures and
standardization of the acceptable ones were undertaken, following the internal procedure at the basis
of the virtual screening database installed on our web server powered by the ChemAxon toolkit [58].
This step specifically consists of the removal of heavy metal-containing species, of high molecular
weight molecules, salts, conversion into the predicted most stable tautomer form, representation of
N-oxides with split formal charges, conversion to the “basic” aromatic forms of 5- and 6-membered
aromatic rings, et .
After standardization, uplicat s (the ame structure, b t differ nt ID ) were identified and
removed. Si ce stereoche istry is not captured by the molecular descriptors (fragment counts),
training sets were reduced to stereochemistry-depleted structures. If several stereoisomers were
present in a set and antimalarial activity was not affected by the stereochemical differences, then
a single entry/stereoisomer was kept. If stereoisomers with widely differing AV were observed, both
were eliminated.
Merging of experimental series into training sets was performed in two steps (Figure 3b,c). First,
experimental series from in-house data and from the ChEMBL database were merged if the six key
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experimental conditions of the protocol, as well as the nature of the reported AV were identical
(Figure 3b). Merging of all of the series tested in an assay based on the same set of six key parameters
(the same protocol) is a logical undertaking. In the absence of a consensus nomenclature of antimalarial
tests, different groups might have run the same assay, although without referring to it by the same
assay identifier. There were five compound series merged at Step 1. Ideally, this merging should have
already happened within the ChEMBL malaria initiative itself and clearly shows the stringent need for
the creation of a common ontology for antimalarial tests. However, even if the tests run by various
groups in different locations did—as far as reported—follow the same conditions, random errors or
even systematic errors due to “hidden” or unreported parameters may have arisen; hence the necessity
to double-check for the coherence of the activities reported for the reference compounds.
Series emerging after Step 1 are each associated to specific experimental conditions. However, in
quest of larger and more robust training sets, a second step of mergers was considered, in order to
join those that contain common compounds (three, at minimum), and the reported AV values of these
compounds are nearly equal (within expected experimental error, 0.5 log units for pIC/pEC measures)
(Figure 3c). By this rule, 20 series (10 pairs) were fused into 10 training sets.
The machine learning strategy has been described in extensive detail [59] and can be considered
as a user guide to the tool in open-access. The evolutionary SVM configurator was used here without
any peculiar adaptation to this work. Interested readers will find a flowchart of the evolutionary
model building scheme in Figure S1 of the Supplementary Material. Since machine learning of
structure-activity relationships requires training sets to be as large and as diverse as possible, separate
modelling of each protocol-specific set may still fall short of the needed critical mass of input data.
This was the primary reason to assess the feasibility of fusing various protocol-specific sets into larger
training sets, at Step 2. This undertaking is however not without risk. On the one hand, the fact that
the activity values for the common reference compounds did not vary from one protocol to the other is,
strictly speaking, only proof that the experimental parameter(s) that were changed have little impact
on the activities of these specific molecules. Their lack of impact with respect to the activity of other
molecules is hypothetic, and this hypothesis is all the more defendable, as the set of common reference
molecules is large, with nearly constant measured activity. On the other hand, if, indeed, antimalarial
screening conditions defining the protocols do have a strong impact, up to the point of witnessing
an “active” compound according to Protocol A being considered “inactive” on Protocol B, then building
separate models for activities measured in each protocol is, technically, the only sound alternative.
However, the biological relevance of contradictory protocols must be addressed: which of Protocols
A and B should, in real life, be trusted when developing an antimalarial drug? This is a non-trivial
question, beyond the scope of this article. If the key protocol parameter is the choice of the P. falciparum
strain, or its development stage, it is expectable to witness measured activities being widely different
from protocol to protocol. However, differences from rather technical parameters (organism strain,
drug exposure time, hematocrit %, parasitemia %, parasitic stage, assay principle, reference substances)
are much more difficult to admit: do protocols differing only at such a level deserve to be considered
as concurrent antimalarial activity evaluators, or should biologist first decide which choice of the
“technical” parameters produces the result most relevant with respect to the actual in vivo activity? It is
also highly unclear whether there is any link between the experimental setups of the antiparasitic tests
and the molecular mechanisms of action involved: are there, for example, some experimental protocols
better at detecting oxidative stress agents, while others preferentially highlight hemozoin formation
inhibitors, etc.? The key difficulty in exploiting the antimalarial data in ChEMBL largely relies on the
delicate question of the interpretation of the various testing protocols. The empirical strategy adopted
in this work, fuse if common compounds seem to be coherently described by two protocols, is not
perfect, but is simple and fact-based. Failure to obtain predictive models for “fused” training sets may
be an indication of the failure of this fusion strategy and vice versa. Note, however, that in the absence
of this fusion strategy, a significant fraction of 55 activity points of data, belonging to rather small
protocol-specific sets (<50 entries) would be lost for model building.
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Eventually, a number of 30 training sets, all selected because (1) each contained more than
50 molecules and (2) they span a significant activity range (i.e., contain both active and inactive), were
saved in the local database (Figure 3d). Some of these sets can be directly traced back to the assay
ChEMBL ID, meaning that these are single source series. They will be further on referred to by the
actual assay ChEMBL ID. Sets regrouping in-house molecules with compounds from one or several
ChEMBL assays considered to be based on a common protocol are fused sets and will be labelled as
“FS”, followed by the protocol ID number as listed in the in-house database. Moreover, fused sets
regrouping entries tested in different, but allegedly compatible protocols will be named “FS” followed
by the “+”-separated concatenation of the merged protocol numbers.
4.2. Knowledge Extraction by the Construction of Structure-Activity Models
Selected training sets were subjected to predictive model building. The large heterogeneity in
reported AVs (IC50, EC50, etc.) and experimental protocols limited the possibility to use quantitative
regression models. Therefore, the modelling strategy had to be modified to attempt categorical model
building, i.e., obtaining mathematical equations that return, for any given compound encoded by
its molecular descriptor, a simple “verdict”, “active” or “inactive”, rather than an estimate of the
actual pIC50 or pEC50. In order to build categorical models, the real-value activity data associated with
training set compounds needed first to be “binned”, i.e., converted to a binary class label (2 = active,
1 = inactive). This has been achieved for each training set by picking the best suited cut-off values
separating “active” from “inactive”: on the log scale (from 7.5 to 6.0) used to report the respective activity
values, cutoffs ranging from the micromolar scale were steadily increased by steps of 12 log until the
“active” ones above the threshold were found to represent between 1/3 and 1/4 of the entire set.
Compounds in each set were encoded under the form of molecular descriptors. Since it is not
a priori known which description strategy will be best suited to specifically capture the chemical
information that best explains the antimalarial activity, a series of 39 distinct ISIDA fragment
descriptor [60] sets was generated for each training set. ISIDA (for in silicon Design and data
Analysis) is a collaborative project devoted to development of new methods and original software
tools for structure—property modelling and computer-aided design of new compounds [60–62].
These 39 description schemes are the same as used in a previous work [61] and found suitable to model
a large range of different biological properties. They correspond to different fragmentation strategies,
using both default (by atom type), pharmacophore and force field type-based atom coloring [62].
Selecting the actual descriptor space for modelling of each set is considered as an explicit degree of
freedom of the evolutionary optimizer tool [58] for the LIBSVM support vector machine algorithm [63]
used here. The tool was applied to each of the 30 training sets, with default control parameters, and it
produced, for each set, a family of SVM classification models by simulating the Darwinian competition
of “chromosomes” encoding model building recipes (choice of descriptors out of the 39 initial options,
choice of kernel type, cost parameter, etc.; see the cited work for an exhaustive discussion on the
technical issues related to SVM model fine-tuning). Emerging models were ranked by a “fitness”
score, which is an expression of the mean balanced accuracy of classification achieved during the
repeated, three-fold cross-validation. Note that, due to the mechanism of extensive cross-validation
used during the model building stage, the herein obtained predictive models are always consensus
models, e.g., they are a collection of several independent predictive equations, each calibrated on
random subsets of the training set and then challenged to predict the remaining items, kept out during
the calibration phase. The fitness score, too, is an averaged balanced accuracy term, penalized by
the standard deviation of the balanced accuracy of individual models (therefore, the actual balanced
accuracy values are slightly higher than the actual fitness scores reported here, but this is not of
practical relevance).
For 17 of the 30 initial sets, the top models with fitness scores exceeding 0.7 were obtained (note
that a balanced accuracy level of 0.5 corresponds to random classification, whereas 1.0 stands for
flawless classification of all active and inactive ones). These 17 sets are listed in Table 3, together with
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the thresholds used to define active and inactive classes, the number of them herewith considered
active and the fitness score of the top consensus model found by the evolutionary SVM tuning tool.
The experimental conditions of the one or several compatible test protocols associated with each
training set can be taken from Table S3.
Table 3. SVM classification consensus model parameters.
Training Set Activity Threshold(log Unit) Size No. of Active
Cross-Validated
Model Fitness Score
FS53 7.0 94 25 0.953
FS39+52 6.0 107 31 0.912
FS31 7.5 65 19 0.910
FS33+67 6.5 70 17 0.905
FS78 7.5 66 27 0.870
FS61 7.0 143 58 0.865
FS15 7.0 116 35 0.849
FS34 7.0 123 33 0.825
CHEMBL896244 7.0 225 74 0.819
FS10 7.0 59 14 0.796
FS76 7.5 160 57 0.787
CHEMBL1038869 6.5 159 43 0.730
CHEMBL730080 6.0 977 273 0.728
CHEMBL896245 7.0 113 37 0.721
CHEMBL730081 6.5 164 41 0.711
CHEMBL730641 6.5 158 51 0.702
CHEMBL1038870 6.5 156 36 0.701
4.3. Virtual Screening of Candidate Collections and the Selection of Candidates with the Best Predicted
Properties Using the Above-Built Models
Virtual screening was used to prioritize putatively active compounds within the series of novel
DAAs and 2,6-DATHTPs. This series is already large enough to require a substantial biological testing
budget for its exhaustive evaluation. The goal of virtual screening-based prioritization was to select
the most likely active and therefore significantly reduce the screening effort.
Each of the above-built 17 SVM classification models are consensus approaches. Every predictor
of each of the 17 properties is based on a family of different mathematical equations, each contributing
one “vote” according to the category (active or inactive, with respect to the current properties) in
which a candidate should be assigned. Therefore, the 17 consensus models return a real-value
likelihood (percentage) of the candidate to qualify as active with respect to the associated property.
Compounds were considered active if at least one model gave the likelihood to be active >70% or more
than one model predicted the likelihood to be active >50%. If, for one property, more than 70% of
the individual predictive equations forming the consensus model “agree” on labelling a compound
as active, this implicitly means that the prediction is internally coherent. A low standard deviation
of the predicted values stemming from individual contributors to a consensus model, which is here
equivalent to “majority voting” being observed, is a strong indicator that the external molecules fall
within the applicability domain of the approach [33]. In fine, using this approach, 40 compounds
(26 DAAs and 14 2,6-DATHTPs) were predicted to be active and 32 compounds not to be active against
the 3D7 P. falciparum strain (Tables 1 and 2).
4.4. Experimental Testing of Selected Candidates
In vitro biological assays. Compounds were tested to establish a full dose-titration and
determination of the IC50. The in-test concentration of DMSO did not exceed 0.5%. The selectivity
antiprotozoal potential on P. falciparum (3D7 strain) was assessed by simultaneous evaluation of
cytotoxicity on a fibroblast (MRC-5) cell line.
Antiplasmodial activity. The P. falciparum 3D7 strain was maintained in O+ human erythrocytes
in albumin RPMI-supplemented medium under continuous culture using the candle-jar method [64].
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The parasites were synchronized to the ring stage by repeated sorbitol treatment [65]. A 2.5% (v/v)
erythrocyte suspension with 1% parasitemia (number of parasites per 100 red blood cells) was
incubated with the compounds to be tested, previously dissolved in DMSO. Parasites were also
incubated with culture medium (negative control) or with 4 µM chloroquine (positive control) in
96-well culture plates. After 44 h of incubation at 37 ˝C, the plates were subjected to 3 freeze-thaw
cycles to achieve complete hemolysis. The useful parameter for the monitoring of in vitro susceptibility
is the concentration that inhibits 50% of the parasite’s activity (IC50). The incorporation of SYBR
Green I (Applied Biosystems) in parasite DNA was measured using the Master epRealplex cycler®
(Eppendorf) according to the following program to increase the SYBR Green incorporation: 90 ˝C
(1 min), decrease in temperature from 90 ˝C to 10 ˝C (during 5 min) with reading the fluorescence.
Then, the IC50 was calculated by icestimator software [66].
Cytotoxicity assay. MRC-5 SV2 cells were cultivated in MEM, supplemented with L-glutamine
(20 mM), 16.5 mM sodium hydrogen carbonate and 5% FCS. For the assay, 104 MRC-5 cells/well were
seeded onto the test plates containing the pre-diluted sample and incubated at 37 ˝C and 5% CO2 for
72 h. Cell viability was assessed fluorometrically after 4 h of the addition of resazurin. Fluorescence was
measured (excitation 550 nm, emission 590 nm), and the results were expressed as % reduction in cell
viability compared to untreated control. Tamoxifen is used as the reference control.
5. Conclusions
Extensive data curation and fusion was primordial to the extraction of large modelable
structure-activity sets, in a context characterized by an extreme heterogeneity of reported antimalarial
assay protocols. Noise-prone activity measures on parasite cultures are intrinsically difficult to
model and are further complicated if data from various sources needs to be merged in order to
reach a critical size of more than 50 compounds per set. Nevertheless, robust classification models
were successfully built and applied for prospective prediction. Even though this academic virtual
screening experiment is of modest scale when compared to high-throughput tests [55], it allowed
successfully reducing the screening effort by a factor of two. The handpicked predicted negative
added to the list of tested compounds has demonstrated the discriminating ability of the virtual
screening procedure. Notwithstanding this practical success, it must be pointed out that models fitted
on the basis of standard parasite culture assays cannot help in elucidating the mechanisms-of-action
of the various compounds. The models only “learn” specific (sub)structural signatures associated
to active and inactive and evaluate novel molecules according to learned patterns. Unfortunately,
in vitro test results targeting specific parasitic targets and pathways are too sparse in public databases
(such as ChEMBL) to be used for mechanism-specific model building. The success of the attempted
virtual screening, in spite of lacking positive proof whether training set compounds included putative
Michael electrophiles acting similarly to the alleged mechanism of curcuminoids, is encouraging:
structure-activity modelling may help even in mechanistically ill-defined noisy experimental contexts.
To conclude, our work allowed predicting and identifying synthetic curcuminoids and derived
2,6-DATHTPs as potent antimalarial motifs to be developed and rationalized in QSAR studies.
Interestingly, the 2,6-DATHTPs derivatives in which the enone groups were masked revealed potent
antimalarial activities and lower cytotoxicity than the parent DAA. In summary, curcuminoids
represent an important and under-utilized series for antimalarial chemotherapy and deserve to be
developed as prodrugs, like 2,6-DATHTPs, or hybrid drugs with two reactive components, an approach
that will pave the way for future development of novel, safe and effective drugs for malaria.
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